Recombinant adeno-associated virus 8 vector in gene therapy:Opportunities and challenges  

作　　者：Liyuan Zhao Zixuan Yang Minhui Zheng Lei Shi Mengyun Gu Gang Liu Feng Miao Yan Chang Fanghua Huang Naping Tang 

机构地区：[1]Anhui University of Traditional Chinese Medicine,Hefei,Anhui 230000,China [2]Yangtze Delta Drug Advanced Research Institute,Yangtze Delta Pharmaceutical College,Nantong,Jiangsu226133,China [3]Shanghai Innostar Bio-Technology Co.,Ltd,China State Institute of Pharmaceutical Industry,Shanghai 201203,China [4]Innostar Bio-tech Nantong Co.,Ltd.,Nantong,Jiangsu 226133,China [5]Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China

出　　处：《Genes & Diseases》2024年第1期283-293,共11页基因与疾病（英文）

摘　　要：In recent years,significant breakthroughs have been made in the field of gene ther-apy.Adeno-associated virus(AAV)is one of the most promising gene therapy vectors and a powerful tool for delivering the gene of interest.Among the AAV vectors,AAV serotype 8(AAv8)has attracted much attention for its efficient and stable gene transfection into specific tissues.Currently,recombinant AAv8 has been widely used in gene therapy research on a va-riety of diseases,including genetic diseases,cancers,autoimmune diseases,and viral diseases.

关 键 词：AAV8 Adeno-associated virus Gene therapy PRIMATES 

分 类 号：R456[医药卫生—治疗学]